{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092279","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.230595+00:00","generated_at":"2026-05-31T11:55:20.316513+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"NewAmsterdam reports positive Phase 3 BROOKLYN data; Q2 net loss $39M","bullets":["Phase 3 BROOKLYN met primary endpoint: LS mean LDL-C reduction 36.3% at day 84 (p<0.0001), sustained at day 365 (-41.5%); safety comparable to placebo.","US composition of matter patent issued for obicetrapib, extending IP protection to July 2043.","Cash $430.7M as of June 30, 2024 (up from $340.5M at Dec 31, 2023).","Q2 net loss $39.0M ($0.41 diluted EPS) vs $38.3M ($0.47) year ago; revenue $2.3M (vs $1.7M).","Topline data for Phase 3 BROADWAY expected Q4 2024; Phase 3 TANDEM enrollment completed, topline Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092279","json":"https://secwatch.observer/filing/0000950170-24-092279.json","markdown":"https://secwatch.observer/filing/0000950170-24-092279.md","text":"https://secwatch.observer/filing/0000950170-24-092279.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024092279/0000950170-24-092279-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024092279/nams-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:55:20.316513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}